Reacción a "EMA recommends not approving donanemab for Alzheimer's"

People living with Alzheimer’s disease in Europe will no doubt be disappointed by the decision from the European Medicines Agency not to approve donanemab, a new treatment for early Alzheimer’s disease.  This medicine has been shown in clinical trials to moderately slow progression of Alzheimer’s symptoms, but it does come with risk of brain swelling and bleeding. There is hope from ongoing scientific research that safer, more effective medicines will be developed in the future.